1. Home
  2. PTMN vs GNFT Comparison

PTMN vs GNFT Comparison

Compare PTMN & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PTMN
  • GNFT
  • Stock Information
  • Founded
  • PTMN 2006
  • GNFT 1999
  • Country
  • PTMN United States
  • GNFT France
  • Employees
  • PTMN N/A
  • GNFT N/A
  • Industry
  • PTMN Finance: Consumer Services
  • GNFT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PTMN Finance
  • GNFT Health Care
  • Exchange
  • PTMN Nasdaq
  • GNFT Nasdaq
  • Market Cap
  • PTMN 152.6M
  • GNFT 172.2M
  • IPO Year
  • PTMN N/A
  • GNFT 2019
  • Fundamental
  • Price
  • PTMN $16.77
  • GNFT $3.61
  • Analyst Decision
  • PTMN Hold
  • GNFT Strong Buy
  • Analyst Count
  • PTMN 3
  • GNFT 1
  • Target Price
  • PTMN $19.33
  • GNFT $13.00
  • AVG Volume (30 Days)
  • PTMN 34.7K
  • GNFT 3.8K
  • Earning Date
  • PTMN 03-13-2025
  • GNFT 09-19-2024
  • Dividend Yield
  • PTMN 16.48%
  • GNFT N/A
  • EPS Growth
  • PTMN N/A
  • GNFT N/A
  • EPS
  • PTMN 0.39
  • GNFT 0.47
  • Revenue
  • PTMN $65,828,000.00
  • GNFT $86,225,222.00
  • Revenue This Year
  • PTMN N/A
  • GNFT $145.20
  • Revenue Next Year
  • PTMN N/A
  • GNFT N/A
  • P/E Ratio
  • PTMN $43.41
  • GNFT $7.47
  • Revenue Growth
  • PTMN N/A
  • GNFT 175.45
  • 52 Week Low
  • PTMN $15.94
  • GNFT $3.35
  • 52 Week High
  • PTMN $20.84
  • GNFT $6.42
  • Technical
  • Relative Strength Index (RSI)
  • PTMN 54.46
  • GNFT 47.76
  • Support Level
  • PTMN $16.05
  • GNFT $3.35
  • Resistance Level
  • PTMN $16.88
  • GNFT $3.66
  • Average True Range (ATR)
  • PTMN 0.23
  • GNFT 0.11
  • MACD
  • PTMN 0.09
  • GNFT 0.04
  • Stochastic Oscillator
  • PTMN 73.71
  • GNFT 63.64

About PTMN Portman Ridge Finance Corporation

Portman Ridge Finance Corp Inc is a non-diversified closed-end investment company. The company originates, structures, and invests in secured term loans, bonds or notes, and mezzanine debt primarily in privately-held middle market companies but may also invest in other investments such as loans to publicly traded companies, high-yield bonds, and distressed debt securities. The company's investment objective in the Debt securities portfolio is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt, and selected equity investments in privately-held middle market companies.

About GNFT GENFIT S.A.

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

Share on Social Networks: